The latest focusIR Investor Webinar with speakers from: Pyx Resources, Helix Exploration, Fulcrum Metals and Metals One takes place on Tuesday 23rd July. Please register here.

Less Ads, More Data, More Tools Register for FREE

Faron Pharma celebrates positive read-out in ongoing MDS trial

Mon, 20th May 2024 09:03

(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form of cancer.

The Turku, Finland-based clinical-stage biopharmaceutical company said the phase 2 read-out confirmed positive phase 1 findings in patients that have failed a hypomethylating agent (HMA), which is also known as relapsed/refractory MDS.

Myelodysplastic syndrome is a form of cancer in which immature blood cells in the bone marrow fail to mature or become healthy blood cells.

"The BEXMAB phase 1 results have already indicated a high overall response rate of 87.5% amongst HMA-failed MDS patients treated with a combination of bexmarilimab + azacitidine," Faron Pharma said.

"Bexmarilimab is a promising agent that works by modulating the immune system and in early data from the ongoing clinical trial in MDS appears to have a very good safety profile and promising clinical activity, especially in median survival after HMA failure. While these are early data and in a small number of patients, if these findings continue to hold up, they would position bexmarilimab to potentially fill a very important clinical gap in the management of MDS patients," said Amer Zeidan, associate professor of Medicine, chief of Hematologic Malignancies Division, director of Hematology Early Therapeutics Research, and leader of the clinical program and the clinical research team for Leukemia & Myeloid Malignancies at Yale Cancer Center.

Faron Pharma shares rose 12% to 280.90 pence each on Monday morning in London.

By Tom Budszus, Alliance News slot editor

Comments and questions to

Copyright 2024 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
11 Jul 2024 19:23

TRADING UPDATES: Titon warns on trading; Videndum revenue in-line

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

11 Jul 2024 11:48

Faron gets positive FDA feedback on bexmarilimab study plans

(Sharecast News) - Faron Pharmaceuticals announced positive feedback from the FDA regarding the clinical development plan for its drug candidate bexma...

11 Jul 2024 10:08

AIM WINNERS & LOSERS: Titon falls amid subdued housing market demand

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Thursday.

4 Jun 2024 11:24

AIM WINNERS & LOSERS: Vast Resources touts progress across mines

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.